Creative Biolabs Advances Antibody Non-GMP Production and Quality Control Excellence
TL;DR
Creative Biolabs offers a competitive edge in the antibody production market with its high-quality, research-grade antibodies and specialized QC services, reducing GMP overhead for clients.
Creative Biolabs employs a detailed process from sequence to purification, ensuring antibody production meets specific requirements like mutation, type, and host selection with up to 95% purity.
By advancing antibody production and QC, Creative Biolabs contributes to safer, more effective therapeutic treatments, improving global health outcomes and future medical research.
Creative Biolabs' 2025 Scholarship Program is a golden opportunity for students in biology and related fields to shine in the next generation of science stars.
Found this article helpful?
Share it with your network and spread the knowledge!
In response to the World Health Organization's emphasis on the importance of quality control in antibody production, Creative Biolabs has positioned itself as a leader in the non-GMP antibody production sector. This initiative is designed to meet the growing demand for flexible, high-quality research-grade antibodies, offering a solution to the challenges of GMP overhead for global clients.
The company's focus on quality control is underscored by research findings on PubMed regarding glycosylation's impact on antibody efficacy and safety. A scientist at Creative Biolabs highlighted the dual drivers behind their custom antibody production and QC service pipeline: the increasing research interest in related areas and the scarcity of professional solutions in the market.
Creative Biolabs is committed to accelerating the development of therapeutic monoclonal antibody candidates through comprehensive management of both upstream and downstream processes. Their OmicsAb™ High-throughput Antibody Production system is a testament to this commitment, enabling the rapid production of diverse antibody candidates without compromising on quality. The system ensures the delivery of target antibodies with specific characteristics, including high purity levels of up to 95%.
Furthermore, the company excels in the production and quality control of multispecific antibodies, from bispecifics to more complex constructs. Their expertise facilitates drug target and delivery, enhances binding specificity, and minimizes off-target toxicity. The scFv-Fc fusion platform offered by Creative Biolabs combines agility with precision, providing clients with convenient fusion formats and comprehensive QC, making 'plug-and-play' experiments a reality.
Beyond its contributions to antibody production, Creative Biolabs is also investing in the future of science through its 2025 Scholarship Program. This initiative supports students in biology, biotechnology, biochemistry, and related fields, showcasing the company's dedication to fostering the next generation of scientific talent.
For more information on Creative Biolabs and their services, visit https://www.creativebiolabs.net/.
Curated from 24-7 Press Release
